Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2015
At a glance
- Drugs Tamibarotene (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 21 Jul 2011 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 14 May 2010 New trial record